SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001624422-23-000046
Filing Date
2023-10-05
Accepted
2023-10-05 07:32:04
Documents
6
Period of Report
2023-10-04

Document Format Files

Seq Description Document Type Size
1 6-K phxm_6-kx10042023.htm 6-K 19900
2 EX-99.1 ex-991phxm_6xkx10042023.htm EX-99.1 18294
3 EX-99.2 ex-992phxm_6xkx10042023.htm EX-99.2 8958
4 GRAPHIC image.jpg GRAPHIC 7189
5 GRAPHIC imagea.jpg GRAPHIC 7189
6 GRAPHIC vetophage.gif GRAPHIC 5128
  Complete submission text file 0001624422-23-000046.txt   75673
Mailing Address 60 AVENUE ROCKEFELLER BATIMENT ADENINE LYON I0 69008
Business Address 60 AVENUE ROCKEFELLER BATIMENT ADENINE LYON I0 69008 011-33-4-78-74-44-38
PHAXIAM Therapeutics S.A. (Filer) CIK: 0001624422 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38281 | Film No.: 231309824
SIC: 2836 Biological Products, (No Diagnostic Substances)